TICKERNERD
Menu
AXGNAXGNHealthcare · Medical Devices

AXGN Stock Forecast: AxoGen, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$49
+1.42% on the day

The 9 Wall Street analysts covering AxoGen, Inc. hold a median 12-month price target of $55 — +12.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.6B
Ticker Nerd rank
81 / 100
Median analyst target
$55
Analysts covering
9
Total return, dividends reinvested
1W
+5.0%
1M
+25.7%
YTD
+48.9%
1Y
+227.0%
From 52W high
−1.9%
From 52W low
+229.5%
$15
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AXGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AxoGen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Volatility
75
Quality
74
Issuance
73
Accruals
62
Value
56
Revisions
56
Growth
52
Size
33

Momentum (100): The shares have been drifting up relative to others.

Growth (52): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AXGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AXGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26AXGNHigh $58Median $55Low $48

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $48Median $55High $58

The green dot is the last close — the median target sits +12.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Canaccord GenuityMaintainsBuy$50 → $55
30 July 2026CitizensMaintainsMarket Outperform$50 → $55
30 July 2026HC Wainwright & Co.MaintainsBuy$50 → $53
29 Apr 2026Canaccord GenuityMaintainsBuy$45 → $50
29 Apr 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026CitizensMaintainsMarket Outperform$42 → $50
29 Apr 2026CitizensMaintainsMarket Outperform—
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
29 Apr 2026HC Wainwright & Co.MaintainsBuy$39 → $50
29 Apr 2026Wells FargoMaintainsOverweight—
29 Apr 2026Wells FargoMaintainsOverweight$40 → $48
23 Apr 2026Lake StreetMaintainsBuy$40 → $50
23 Apr 2026Lake StreetMaintainsBuy—
30 Mar 2026Canaccord GenuityMaintainsBuy—
24 Feb 2026CitizensMaintainsMarket Outperform—
19 Feb 2026Wells FargoInitiatesOverweight—
5 Dec 2025Canaccord GenuityMaintainsBuy—
5 Dec 2025HC Wainwright & Co.MaintainsBuy—
4 Dec 2025JefferiesMaintainsBuy—
4 Dec 2025Lake StreetMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AXGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AXGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−6.2%
Analysts raising
1
Analysts cutting
4
Fundamentals

AxoGen, Inc. (AXGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−143.4×

Cheaper than 99% of US stocks

Price / sales
10.4×

Cheaper than 14% of US stocks

Price / book
10.2×

Cheaper than 10% of US stocks

EV / EBITDA
−423.7×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
23.1%

Higher than 73% of US stocks

Earnings growth (YoY)
23.1%

Higher than 62% of US stocks

Gross margin
72.7%

Higher than 85% of US stocks

Operating margin
−3.1%

Higher than 29% of US stocks

Net margin
−13.4%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−18.2%

Higher than 32% of US stocks

Return on assets
−3.1%

Higher than 34% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AXGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AXGNAxoGen, Inc.$2.6B
81
NEOGNeogen Corp.$2.6B
94
UFPTUFP Technologies, Inc.$2.5B
75
BFLYButterfly Network, Inc.$2.4B
72
ALMRAlamar Biosciences, Inc. (California)$2.3B
4
ESTAEstablishment Labs Holdings, Inc.$2.2B
76
TMDXTransMedics Group, Inc.$3.1B
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AxoGen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AXGN news & analysis

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel

Seeking Alpha · 3 Aug 2026positive

Axogen reported Q2 2026 revenue of $69.7M, up 23.1% year over year, and raised its full-year guidance amid strong elective market traction, though gross margin declined due to product mix and biologic costs. The FDA's biologic approval of Avance provides 12 years of exclusivity, greater regulatory credibility, and improved payer coverage, as Axogen positions itself as a comprehensive nerve care platform.

Why it matters — Axogen watchers would care because the FDA approval of Avance with 12 years of exclusivity and stronger reimbursement may give the company a durable regulatory advantage and a path to category leadership in the nerve repair market.

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 29 July 2026neutral

Axogen, Inc. held its Q2 2026 earnings call, and the transcript was published on Seeking Alpha.

Why it matters — Earnings call transcripts provide AXGN watchers with detailed management commentary and financial results for the quarter.

AxoGen Q2 Earnings Call Highlights

MarketBeat · 29 July 2026neutral

AxoGen reported second-quarter 2026 revenue of $69.7 million, a 23.1% increase from the prior year, and raised its full-year revenue outlook to at least $279 million. The company lowered its gross-margin expectation to at least 73%, citing product-mix changes from faster-than-expected growth in breast reconstruction.

Why it matters — AXGN watchers would note the raised revenue guidance alongside the lowered gross-margin forecast, reflecting how strong demand in certain segments is reshaping the company's product mix and profitability outlook.

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

Zacks Investment Research · 29 July 2026positive

AxoGen reported Q2 earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share, and matching its earnings from the same quarter last year.

Why it matters — The earnings beat suggests AxoGen's quarterly performance exceeded analyst expectations, which may be of interest to shareholders tracking the company's financial trajectory.

Axogen, Inc. Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 29 July 2026neutral

Axogen, Inc. reported its financial results for the second quarter of 2026, as announced in a GlobeNewsWire release from the company's locations in Alachua and Tampa, Florida.

Why it matters — Quarterly financial results provide insight into Axogen's recent performance and operational trends, which are key indicators for stakeholders monitoring the company's progress.

FAQ

Frequently asked questions about AXGN stock

What is the AXGN stock price forecast for 2026-2027?

The 9 Wall Street analysts covering AxoGen, Inc. have a median 12-month price target of $55, with estimates ranging from $48 to $58. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AXGN stock a buy right now?

Of the 9 analysts covering AxoGen, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AxoGen, Inc. 81 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AXGN?

As at 13 Aug 2026, AxoGen, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will AXGN stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +12.9% from the last close, and Ticker Nerd's factor model ranks AxoGen, Inc. 81 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AXGN stock forecast for 2030?

No analyst covering AxoGen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $58 over the next 12 months.

How has AXGN stock performed over the past year?

AxoGen, Inc. returned +227.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AxoGen, Inc. do?

Axogen Inc. is a leading developer and marketer of innovative surgical solutions for peripheral nerve regeneration and repair.

What is the latest news on AXGN?

The most recent item we track (Seeking Alpha, 3 Aug 2026): "Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel". Axogen reported Q2 2026 revenue of $69.7M, up 23.1% year over year, and raised its full-year guidance amid strong elective market traction, though gross margin declined due to product mix and biologic costs. The FDA's biologic approval of Avance provides 12 years of exclusivity, greater regulatory credibility, and improved payer coverage, as Axogen positions itself as a comprehensive nerve care platform.

Company

About AxoGen, Inc.

Axogen Inc. is a leading developer and marketer of innovative surgical solutions for peripheral nerve regeneration and repair. The company specializes in biologically active technologies, including the Avance Nerve Graft, an off-the-shelf processed human nerve allograft that bridges severed peripheral nerves without requiring a second surgical site. Its portfolio also features the AxoGuard Nerve Connector and AxoGuard Nerve Protector, porcine submucosa extracellular matrix products that enable tensionless nerve repairs and protection; the AxoGuard Nerve Cap for nerve end treatment; and the Avive Soft Tissue Membrane for soft tissue management. Additionally, Axogen offers the AxoTouch Two-Point Discriminator, a tool for assessing skin innervation density. These products serve hand surgeons, reconstructive plastic surgeons, oral and maxillofacial surgeons, and other specialists treating nerve injuries across the body. Axogen Inc. provides these solutions to healthcare providers in the United States, Canada, Europe, South Korea, and other international markets, aiming to restore nerve function, sensation, and patient quality of life. Headquartered in Alachua, Florida, the company focuses on advancing peripheral nerve repair as a standard of care in surgical practice.

CEO Mr. Michael D. Dale · 622 employees · United States · https://www.axogeninc.com